Furthermore, patients experiencing frequent hypoglycemia, poor glycemic control on current insulin regimens, or those using complex treatment strategiessuch as multiple daily injectionsmay benefit from a switch to a simplified regimen with combination basal insulin and GLP-1 agonists [36]
Weight loss medications can be expensive, especially new ones
[1] Other recognised side effects include: Injection site reactions (erythema, pruritus, swelling) Decreased appetite (which contributes to the weight loss effect) Fatigue and dizziness Increased heart rate (modest increases observed in clinical trials) Hypoglycaemia (particularly when used with insulin or sulfonylureas) Serious but rare adverse effects include pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting), gallbladder disease (right upper quadrant pain, nausea, vomiting), and potential thyroid C-cell tumours (observed in rodent studies, though relevance to humans remains uncertain)
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial
Against Eden's all-in figures of $198 and $298 (July 2026), the injectable protocols sit modestly lower, and they add pathway-level genetic context through the Precision Peptide Genetic Test that Eden does not offer
.jpg?sfvrsn=f85d055_0)
